News and insights
223 81 Lund, Sverige
+46 46-15 21 00
©Copyright 2024 CLS AB. All rights reserved.
A tumor in the brain means major challenges – for the patient and for healthcare. In addition, it may be poorly localized making surgery difficult. Passing various nerve centers that control important functions of the body is critical. Supplementary treatment with chemotherapy and radiation is generally needed.
When using laser ablation in neurosurgery, so called laser interstitial thermal therapy (LITT), a region of interest is directly targeted and treated with high precision. Areas in the brain, not accessible for open surgery, can be treated as LITT is typically minially invasive through use of MRI guidance (MRgLITT), and a stereotactic access system.
In collaboration with partners and through clinical programs, CLS is expanding into MRgLITT for treatment of patients with tumors and other lesions in the brain, including epileptogenic foci.
A system for MRI guided laser ablation in neurosurgery is cleared by the US Food and Drug Administration (FDA) as of September 22, 2022. It is commercialized by our partner ClearPoint Neuro Inc. under the brand name ClearPoint Prism™ Neuro Laser Therapy System, starting in the USA.
The new system includes CLS’s:
A clinical study at Skåne University Hospital, Lund , evaluating safety and feasibility using the CLS system for MRgLITT in minimally invasive ablation of lesions in the brain, such as primary tumors of patients diagnosed with glioblastoma, is now recruiting patients.
Glioblastoma is the most aggressive brain tumor and almost incurable. Despite intensive research and drug development the treatment of this disease remains a challenge. Hence, the need for new treatment options to offer affected patients is huge.
Our goal is to develop the field of therapy – by offering tools for precise and cost-efficient treatment.
For CLS it has been an intense start to the year with many positive news. Read about what has been happening with a focus on actions to future proof our core technology, an update on market expansion, andew company presentations.
The Holiday Season is approaching, and it is time for some reflections and to sum up the year 2023 - and what a year it has been for all of us at CLS, our clinics and all the patients treated with our TRANBERG systems!
For CLS this meeting offered a perfect opportunity to meet with both the leading experts, and with clinicians about to introducing focal therapy in their clinic.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region